A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

BACKGROUND: Luteinising hormone-releasing hormone agonists (LHRHa), used as androgen deprivation therapy (ADT) in prostate cancer (PCa) management, reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss. Transdermal oestradiol is a potential alternative to LHRHa. OB...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Urol
Main Authors: Langley, Ruth E., Kynaston, Howard G., Alhasso, Abdulla A., Duong, Trinh, Paez, Edgar M., Jovic, Gordana, Scrase, Christopher D., Robertson, Andrew, Cafferty, Fay, Welland, Andrew, Carpenter, Robin, Honeyfield, Lesley, Abel, Richard L., Stone, Michael, Parmar, Mahesh K.B., Abel, Paul D.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier Science 2016
Assuntos:
Platinum Priority – Prostate Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4854173/
https://ncbi.nlm.nih.gov/pubmed/26707868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2015.11.030
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados